GILEAD SCIENCES, INC. Deferred Tax Assets, Deferred Income
GILEAD SCIENCES, INC. (GILD) had Deferred Tax Assets, Deferred Income of $0 as of 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2019-02-26
- 2018-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2017-12-31: Deferred Tax Assets, Deferred Income $27.00M.
- 2016-12-31: Deferred Tax Assets, Deferred Income $56.00M.
- 2015-12-31: Deferred Tax Assets, Deferred Income $55.00M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-26 | |
| 2017-12-31 | $27.00M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $56.00M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $55.00M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $46.00M 10-K · filed 2016-02-24 | |
| 2013-12-31 | $42.00M 10-K · filed 2015-02-25 | $42.39M 10-K · filed 2014-02-25 |
| 2012-12-31 | $39.90M 10-K · filed 2014-02-25 | |
| 2011-12-31 | $37.31M 10-K · filed 2013-02-27 | |
| 2010-12-31 | $49.19M 10-K · filed 2012-02-23 | |
| 2009-12-31 | $67.39M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |